Who Optimizes SG&A Costs Better? Jazz Pharmaceuticals plc or CRISPR Therapeutics AG

Optimizing SG&A Costs: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Jazz Pharmaceuticals plc and CRISPR Therapeutics AG, two prominent players in the industry, have shown contrasting trends in their SG&A expenses over the past decade.

From 2014 to 2023, Jazz Pharmaceuticals consistently reported higher SG&A expenses, peaking at approximately $1.45 billion in 2021. This represents a staggering increase of over 250% from their 2014 figures. In contrast, CRISPR Therapeutics AG, while also experiencing growth in SG&A costs, maintained a more modest increase, reaching around $102 million in 2021, a nearly 20-fold rise from 2014.

These trends highlight Jazz Pharmaceuticals' aggressive expansion strategy, while CRISPR Therapeutics AG appears to focus on leaner operations. Understanding these dynamics offers valuable insights into the strategic priorities of these biotech leaders.